Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free

Phase 3

Alcon Research (ALC)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

ALCPhase 3$31.9B

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free Phase 3 Est. Readout

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free• Ocular Hyperemia230

Feb 2027~Confirmed

CT.gov

00%

Jan '27

ALCPhase 3$31.9B

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free Phase 3 Est. Readout

Apraclonidine Ophthalmic Solution, Unit Dose Preservative Free• Ocular Hyperemia178

Jan 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Ocular Hyperemia

View Full Landscape

Drug Information

Target Indication

Ocular Hyperemia

Clinical Trial

NCT07578363

Last updated: 10/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Travoprost/Timolol maleate ophthalmicPhase 3

Glaucoma, Open-angle

Brinzolamide ophthalmicPhase 3

Open-Angle Glaucoma

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Travoprost, InvestigationalPhase 3

Open-angle Glaucoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts